Acinetobacters are important nosocomial opportunists, particularly in intensive care and other specialist units. Common infections include ventilator-associated pneumonias and bacteremias; less frequent sites include burn wounds and the urinary tract (3). Most infections are caused by Acinetobacter baumannii, a species resilient to drying and commonly multiresistant to antibiotics.
Acinetobacters are important nosocomial opportunists, particularly in intensive care and other specialist units. Common infections include ventilator-associated pneumonias and bacteremias; less frequent sites include burn wounds and the urinary tract (3) . Most infections are caused by Acinetobacter baumannii, a species resilient to drying and commonly multiresistant to antibiotics.
A. baumannii strains notoriously cause hospital outbreaks, and a few lineages achieve "epidemic" status, reaching multiple hospitals or countries. By convention, these are termed "clones" rather than "strains" when their relatedness is inferred on the basis of DNA profiles, without proven chains of site-to-site transmission. Examples include (i) the European clones I, II, and III, which are widespread in continental Europe (8, 25) , (ii) a clone with the VEB-1 cephalosporinase that spread in northeast France and Belgium in late 2003 to 2004 (21) , (iii) a clone with OXA-40 (OXA-24) carbapenemase which is prevalent at numerous hospitals in Spain and Portugal (7) , and (iv) the southeast (SE) clone prevalent in southern England since 2000 (24) . Disturbingly, several successful clones are now also carbapenem resistant and, as noted by the Infectious Disease Society of America, Acinetobacter is "a prime example of the mismatch between unmet medical need and the current antimicrobial research and development pipeline" (22) .
Among consecutive A. baumannii isolates collected at 54 United Kingdom hospitals in 2000 more than 85% were resistant to cephalosporins, 43% were resistant to gentamicin, and 46% were resistant to quinolones, leaving the carbapenems as the only standard antibiotics active against more than 90% of isolates in vitro (11) . However, the SE clone, which began to become prevalent shortly after the study period for this survey Isolate characterization. DNA fingerprinting was by pulsed-field gel electrophoresis (PFGE) of ApaI-digested genomic DNA (24) . Isolates were identified to the genospecies level by amplified rRNA gene restriction analysis (10, 26) and tRNA spacer fingerprinting (10) or (mostly) on the basis of having PFGE profiles corresponding to known A. baumannii clones. bla OXA-23 -like genes were sought by PCR using primers and conditions described elsewhere (1, 4, 6) or in parallel with those for other OXA carbapenemases (bla OXA-24 , bla OXA-51 , and bla OXA-58 ) using a multiplex assay (27) . Sequencing of bla OXA-23 -like genes was performed on a CEQ 8000 (Beckman-Coulter, High Wycombe, United Kingdom) apparatus as described previously (7). Susceptibility testing was done on IsoSensitest agar (Oxoid, Basingstoke, United Kingdom) according to British Society for Antimicrobial Chemotherapy guidelines (2) . (Table 1) . These were distinct from each other and from the SE clone in PFGE profile (Fig. 1) . Nearly all representatives were positive for the bla OXA-23 -like gene, as well as the bla OXA-51 -like gene, and the two clusters were designated OXA-23 clones 1 and 2. The bla OXA-23 -like gene was sequenced from three representatives of each, from different sites, and was found to have the classical sequence, as in A. baumannii 6B92, collected in Scotland in 1985 (9) .
RESULTS

From
By the end of 2005 we had received 419 and 58 examples of OXA-23 clones 1 and 2, respectively, with the former from 40 Hospital Trusts and the latter from 8. The maximum numbers of isolates from single trusts were 71 (from 63 patients) for clone 1 and 23 (from 20 patients) for clone 2. Five exceptional isolates, in addition to these totals, had PFGE profiles corresponding to OXA-23 clone 1 but lacked bla . In all, and since 2000, at least 56 hospital trusts have been affected by one or more of the three clones discussed here.
Both OXA-23 clones were distinct in PFGE profile from the original OXA-23-producing isolate (6B92; labeled sporadic 1 on Fig. 2) and from an OXA-23-producing Brazilian strain (6), included as a control. Both were also distinct from 13 further Acinetobacter isolates that were PCR positive for the bla OXA-23 -like gene and that were received from United Kingdom laboratories during the study period. Most of these were sporadic strains and did not cause outbreaks (e.g., sporadic 2 and 3 in Fig. 1) ; they split into nine distinct clones by PFGE.
Typical members of OXA-23 clones 1 and 2 were notably resistant. Resistance to imipenem and meropenem was more consistent than in the SE clone (Table 2 ) and was unequivocal under British Society for Antimicrobial Chemotherapy criteria (MIC of Ͼ4 g/ml) except for a few members of OXA-23 clone 2. Members of both clones were also consistently resistant to penicillins and penicillin-␤-lactamase inhibitor combinations, cephalosporins, quinolones, gentamicin, tobramycin, tetracycline, and cotrimoxazole and to sulbactam alone (which has some antibiotic activity against many Acinetobacter spp. [15] ). Amikacin was active against OXA-23 clone 2 but not against clone 1, and minocycline had borderline activity against clone 1 while retaining good in vitro activity against clone 2. Tigecycline (18) had MICs of Յ2 g/ml for most of the isolates and was more active against OXA-23 clone 1 isolates (modal MIC, 0.5 g/ml) than against members of the SE clone or OXA-23 clone 2 groups (modal MICs both 2 g/ml) (Fig. 2) . Colistin was active against nearly all members of the two OXA-23 clones and the SE clone at 2 g/ml and was active against most at Յ0.5 g/ml (Fig. 2) .
The few representatives of OXA-23 clone 1 that were negative for the bla OXA-23 -like gene (designated the OXA-23-negative clone 1) were susceptible to imipenem and meropenem (MICs of Յ4 g/ml, Table 3 ), except for one (H170) resistant to meropenem. They also showed increased suscep- 
DISCUSSION
Acinetobacter spp. are notorious both for their ability to acquire antibiotic resistance and for the ability of some strains, mostly strains of A. baumannii, to cause nosocomial outbreaks (3) . Nevertheless, prior to 2000, virtually all A. baumannii isolates in the United Kingdom were susceptible to carbapenems (11) , and very few genotypes appeared to occur in multiple hospitals. These patterns changed with the multicentric isolation of the SE clone, with its variable resistance to imipenem and meropenem (24) . The two OXA-23-producing clones described here represent a further ratcheting of the problem, being more consistently resistant to carbapenems.
The origins of these clones remains unclear, as do the reasons for their epidemic success. It seems likely, particularly in London, that their spread among centers has been via patient transfers, but there is no direct epidemiological proof of this view, and it remains possible that they have arisen at different sites by independent selection from a widespread common ancestor (8), a hypothesis that may explain the observed variation in PFGE profiles between representatives from different centers.
Extracted OXA-23 enzyme has very weak activity against carbapenems; nevertheless, MIC comparisons for members of the OXA-23 clone 1 with or without the bla OXA-23 -like gene (Tables 2 and 3) suggest that the enzyme was responsible for the carbapenem resistance. These conclusions are in keeping with studies showing that carbapenem resistance cotransferred with bla OXA-23 in Acinetobacter (13) , and with data showing that the bla OXA-51 -like gene is not activated by ISAba1 in the OXA-23 clone 1, indicating that it is unlikely to be the real source of resistance (23, 23) .
Although OXA-23 clone 2 now seems to be in decline (Table 1), the reference laboratories continue to receive referrals of OXA-23 clone 1, as well as of the SE clone. Both are causing therapeutic as well as infection control problems. Treatments being used include intravenous colistin, often with nebulized colistin added in pneumonia cases, or tigecycline. Local outcome analyses are in progress. The international literature reports generally good outcomes with intravenous colistin (polymyxin E) against infections caused by multiresistant Acinetobacter spp,. except in pneumonia, where a 75% failure rate was noted (16) . The poor performance with pneumonia probably reflects poor penetration to the lung (16), and there is some evidence that this limitation can be overcome by increased dosage (19) or by the coadministration of nebulized drug (14, 20) . However, neither of these approaches has been validated in formal trials, and higher intravenous doses may increase the risk of nephrotoxicity. It should also be stressed that pharmacodynamic analyses for polymyxins remain very limited and that much of the pharmacokinetic analysis is old and needs to be reevaluated by modern methodologies (17) . In the case of tigecycline, we await analysis of the compassionateuse program, under whose ambit several patients infected with these clones were treated; anecdotally, we are aware both of successes with tigecycline in acinetobacter infections and of a few instances where resistance emerged during therapy but cannot, as yet, relate these to the clone type (18) .
With this background of uncertainty it is unclear as yet whether tigecycline or colistin should be the preferred therapy for infections due to the present clones or other similarly resistant A. baumannii strains; nevertheless, it does seem ap- a Ranges are indicated in parentheses. Bimodal distributions (BM) with distinct resistant and susceptible populations are noted; in these cases, the geometric means are omitted, being meaningless. AMK, amikacin; AMP, ampicillin; CIP, ciprofloxacin; CTX, cefotaxime; CAZ, ceftazidime; GEN, gentamicin; IPM, imipenem; MEM, meropenem; PIP, piperacillin; PTZ, piperacillin-tazobactam; SUL, sulbactam; MIN, minocycline; TIG, tigecycline; COL, colistin. The British Society for Antimicrobial Chemotherapy's breakpoints are given parenthetically in the subheadings in the form "x/y," meaning susceptible is Յx g/ml and resistant is Ͼy g/ml. The Society has no current breakpoint for minocycline or sulbactam versus Acinetobacter spp. and has adopted the European Committee on Susceptibility Testing's (EUCAST; http://www.eucast.org) view that there is as yet "insufficient evidence" to set breakpoints for tigecycline versus Acinetobacter spp. NT, not tested. 
